Abstract
Objectives
Mixing diagnostic and prognostic data provided by whole-body MRI (WB-MRI) and 2-18F-fluorodeoxyglucose (2-[18F]FDG) positron emission tomography (2-[18F]FDG-PET) from a single simultaneous imaging technique for newly diagnosed multiple myeloma (NDMM) initial workup seems attractive. However, to date, the published data are scarce and this possibility has not been fully explored. In this prospective study, we aimed to explore the diagnostic performance and added clinical value of WB-2-[18F]FDG-PET/MRI imaging in NDMM.
Methods
All patients with confirmed NDMM at the Nantes University Hospital were prospectively enrolled in this study and underwent WB-2-[18F]FDG-PET/MRI imaging on a 3-T Biograph mMR before receiving treatment. Before imaging, they were considered either as symptomatic or as smoldering MM (SMM). Diagnostic performance of global WB-2-[18F]FDG-PET/MRI imaging, as well as PET and MRI separately for FL and diffuse BMI detection, was assessed and compared in each group. PET-based (maximal standardized uptake value, SUVmax) and MRI-based (mean apparent diffusion coefficient value, ADCmean) quantitative features were collected for FL/para-medullary disease (PMD)/bone marrow and were compared.
Results
A total of 52 patients were included in this study. PET and MRI were equally effective at detecting patients with FL (69% vs. 75%) and with diffuse BMI (62% for both) in the symptomatic MM group. WB-2-[18F]FDG-PET/MRI imaging detected FL in 22% of patients with SMM (with a higher diagnostic performance for MRI), resulting in a significant impact on clinical management in this population. SUVmax and ADCmean quantitative features were weakly or not correlated.
Conclusions
WB-2-[18F]FDG-PET/MRI could represent the next-generation imaging modality for MM.
Key Points
• Whole-body 2-[18F]FDG-PET/MRI imaging detected at least one focal bone lesion in 75% of patients with symptomatic multiple myeloma, and PET and MRI were equally effective at identifying patients with a focal bone lesion.
• Whole-body 2-[18F]FDG-PET/MRI imaging detected a focal bone lesion in 22% of patients with smoldering multiple myeloma (with a higher diagnostic performance for MRI).
• MRI had a significant impact on clinical management of smoldering multiple myeloma.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Modern imaging techniques are now widely used in newly diagnosed multiple myeloma (NDMM) in order to detect bone disease which is a primary criterion to initiate therapy [1]. In the latest International Myeloma Working Group (IMWG) imaging guidelines [2], both whole-body MRI (WB-MRI) and 2-18F-fluorodeoxyglucose (2-[18F]FDG) positron emission tomography (PET) with computed tomography (CT) imaging techniques can be performed at initial workup.
WB-MRI is highly sensitive for identifying focal bone lesion (FL) — a myeloma-defining event (MDE) — especially at the early smoldering multiple myeloma (SMM) phase [3, 4]. Moreover, MRI imaging does not expose patients to radiation and allows differential diagnosis between osteoporotic and pathological fractures as well as spinal cord compression complication detection. On the other hand, 2-[18F]FDG-PET imaging is also a sensitive imaging technique for FL detection at baseline [5, 6] and provides added crucial prognostic data from the outset [6,7,8,9,10]. Thus, mixing these diagnostic and prognostic data in a single imaging technique seems attractive.
New hybrid simultaneous PET/MRI imaging has emerged over recent years and these devices can substitute the usual CT scan with an MRI scan coupled with PET imaging. The theoretical and practical potential of performing single simultaneous WB-2-[18F]FDG-PET/MRI imaging for NDMM is high, but to date, this has not been fully explored and published data are scarce.
In this prospective study, we aimed to describe our imaging protocol as well as to explore the diagnostic performance and added clinical value of WB-2-[18F]FDG-PET/MRI imaging in NDMM.
Materials and methods
Patients
All patients with confirmed NDMM according to IMWG criteria [1] at the Nantes University Hospital were prospectively enrolled in this study and underwent WB-2-[18F]FDG-PET/MRI imaging between May and December 2021 before receiving treatment. These patients were included in the MYRACLE protocol study as well [11].
Patients with NDMM were considered as symptomatic before the WB-2-[18F]FDG-PET/MRI imaging if any one or more MDE were present: end organ damage attributed to the MM; hypercalcemia, renal insufficiency, anemia, osteolytic bone lesions, and/or biomarkers of malignancy: clonal bone marrow plasma cell percentage ≥ 60%, involved/uninvolved serum free light chain ratio ≥ 100.
If no MDE was present at baseline before the WB-2-[18F]FDG-PET/MRI imaging, patients were regarded as SMM.
This prospective study was approved by a local institutional review board committee. Informed consent was obtained from all individual participants included in the study.
PET/MRI device and imaging protocol
Imaging was carried out using a 3-T Biograph mMR (Siemens).
Simultaneous WB-PET and WB-MRI imaging (from the top of the head down to under the knees or through to the feet, with arms along the body) was performed 55 to 75 min after the 2-[18F]FDG injection (3 MBq/kg). PET data were reconstructed using the 3D ordinary Poisson ordered-subset expectation maximization provided by the manufacturer with 3 iterations, 21 subsets, and Gaussian post-smoothing of 4-mm full width at half maximum (voxel size: 2.1 × 2.1 × 2.0 mm3). The MRI imaging protocol included, as recommended by the international guidelines [12]:
-
WB 3D Gradient Echo T1-weighted magnetic resonance attenuation correction (MRAC) for PET reconstruction and generating fat fraction maps.
-
Whole-spine sagittal T1 TSE-DIXON (slice thickness 4 mm, FOV 280 mm, matrix 256, TR/TE: 750/10 ms) and T2 TSE-STIR weighted (slice thickness 3.5 mm, FOV 280 mm, matrix 320, TR/TE: 4000/59 ms).
-
WB axial diffusion-weighted (DWI) with 2 b values (50 and 800 s/mm2) and apparent diffusion coefficient (ADC) calculation and 3D-MIP reconstructions of highest b-value images, WB axial T2 TSE-STIR weighted (5-mm contiguous slices, FOV 450 mm, matrix 256, TR/TE: 4300/70 ms).
Moreover, dynamic contrast enhanced (DCE)–MRI was performed as previously proposed [13] by injecting a bolus of gadolinium contrast agent of 0.2 mL/kg at an injection rate of 3–5 mL/s. This protocol consists of a 3D acquisition repeated every 3.1 s by use of 3D Gradient Echo sequence (slice thickness 2 mm, FOV 300 mm, matrix 192, TR/TE: 2.32/0.72 ms, flip angle = 12°, 40 repetitions) of the lumbar spine and the sacrum.
PET/MRI assessment
All patients fasted for at least 6 h before the PET/MRI imaging. No dexamethasone was administered within 12 h before the imaging. Blood glucose levels were measured before 2-[18F]FDG injection with a preferred glycemia level ≤ 150 mg/dL; up to 200 mg/dL was allowed. No insulin was administered within 2 h before 2-[18F]FDG injection. Patients could receive a mild sedative orally before 2-[18F]FDG injection as needed. Absolute contraindications to MRI imaging were systematically quested before imaging.
PET images were interpreted by a team of nuclear medicine physicians with extensive experience in MM. FL was defined as foci within bones more intense than normal bone marrow background and present on at least two consecutive slices. Diffuse bone marrow involvement (BMI) was defined as an uptake (homogeneous or heterogeneous) in the axial and appendicular skeleton higher than liver uptake. Extra-medullary disease (EMD) was considered as soft tissue invasion without contiguous bone involvement and paramedullary disease (PMD) as soft tissue invasion with contiguous bone involvement. The number of FL/PMD/EMD lesions was quantified for each as follows: (N = 1), (N = 2), (N = 3), (N = 4), (N = 5 to 10), and (N > 10), as guided by the IMPeTUs criteria [14]. Localizations of the most intense 2-[18F]FDG uptake were identified and the whole-body maximal standardized uptake value (SUVmax) was calculated for FL (SUVmaxFL), PMD (SUVmaxPMD), and EMD (SUVmaxEMD) lesions, using the body weight corrected formulation, for each PET dataset. SUVmaxBM (SUVmax of bone marrow) was measured with regions of interest (ROIs) of similar size (4 cm3) placed inside the vertebral body of L4 or L5 on a single slice (preferentially sagittal) excluding FL when present at this level.
MRI assessment was performed as recommended by international guidelines [12]. FLs greater than 5 mm with appropriate signal characteristics were considered as focal active disease. As for PET imaging, EMD was considered as soft tissue invasion without contiguous bone involvement and PMD as soft tissue invasion with contiguous bone involvement. The number of FL/PMD/EMD lesions was quantified for each as follows: (N = 1), (N = 2), (N = 3), (N = 4), (N = 5 to 10), and (N > 10). True positivity of detected FL was confirmed with follow-up scans.
Diffuse BMI was considered when a diffuse decreased signal on T1-in phase-DIXON weighted and diffuse increased signal throughout the marrow (relative to normal adjacent muscle) on high b-value images were present [15].
Mean values of apparent diffusion coefficient (ADCmean) were recorded for FL (ADCmeanFL), PMD (ADCmeanPMD), and EMD (ADCmeanEMD) lesions with ROIs greater than 1cm2 of similar size placed inside the most intense 2-[18F]FDG uptake lesions for each patient. Moreover, ADCmeanBM (ADCmean of bone marrow) was registered as for PET imaging with ROIs of 4cm2 placed within the vertebral body of L4 or L5 on a single axial slice excluding FL when present at this level.
All MRI images were interpreted by radiologists with extensive experience and specialized skills in osteo-articular imaging. Next, a group of nuclear medicine physicians and radiologists reviewed the imaging outcomes to establish a consensus.
Statistical analysis
Fisher’s exact test was used to assess the differences in detecting FLs and diffuse BMI between PET and MRI. The correlation between continuous quantitative variables extracted from PET and MRI was derived using the Spearman rank correlation coefficient. The optimal MRI-based ADCmeanBM cut-off value to detect BMI on MRI was performed by receiver-operating characteristic (ROC) analysis using the Youden index and considering PET results as the gold standard. Statistical analyses were performed using R version 4.0.3.
Results
Patients
Fifty-two patients with NDMM were consecutively included. Thirty-six (69%) of them had SMM and 16 (31%) symptomatic disease as defined above. Table 1 reports the patient’s clinical and biological characteristics.
Among symptomatic MM patients before the WB-2-[18F]FDG-PET/MRI imaging, 6% had hypercalcemia, 31% renal insufficiency, 69% anemia, and 38% bone disease. Three patients had only a biomarker of malignancy (involved/uninvolved serum free light chain ratio ≥ 100) without end organ damage attributed to the MM.
PET/MRI assessment
Total acquisition time was approximately 1 h for each patient. Acquisition was stopped for one patient due to pain; only a subset of images was obtained for this patient.
The performance of WB-2-[18F]FDG-PET/MRI imaging for FL and diffuse BMI detection is reported in Table 2. In the whole population, WB-2-[18F]FDG-PET/MRI imaging detected diffuse BMI and at least one FL in 26/52 (50%) and 20/52 (38%) of patients respectively.
In symptomatic MM patients, FL and diffuse BMI detection rates were roughly equal between PET and MRI. WB-2-[18F]FDG-PET/MRI imaging detected FL in 75% of patients and diffuse BMI in 62% of patients. Among patients with FL (69% for PET and 75% for MRI, p = 0.5), MRI identified more FLs (3 patients more with > 10FL and one more with 5 to 10 FL, Table 3).
In the SMM population, WB-2-[18F]FDG-PET/MRI imaging identified FL in 8/36 (22%) of patients (Figs. 1 and 2), leading to an impact on clinical management. Four/36 (11%) of these patients had FL only detected by MRI (Fig. 1). Among them, two patients had 3 FL, one 4 FL, and one more than 10 FL (Table 3). No association was established between MRI and PET for diffuse BMI detection (p = 0.136) in the SMM population, and PET detected more diffuse BMI than MRI (36% vs. 22%) (Fig. 3).
EMD was never detected in the whole population. Five/16 (31%) of the symptomatic MM patients had PMD detected each time by both PET and MRI imaging with equal numbers of lesions. PMD was never detected in SMM patients (Table 3).
Quantitative features
Quantitative features recorded by PET and MRI imaging are presented in Table 4. Median ADCmeanFL was 768µm2/s in the symptomatic MM patients and 727µm2/s in SMM patients. Median ADCmeanBMI was 467µm2/s in both groups.
SUVmaxBM and ADCmeanBM were weakly positively correlated (r = 0.48, p = 0.00036, Figure S1) whereas SUVmaxFL and ADCmeanFL were not correlated (Figure S2). There was a trend to a negative correlation between SUVmaxPMD and ADCmeanPMD (r = − 0.9, p = 0.083, Figure S3), ADCmeanPMD decreasing when SUVmaxPMD increased. In the total NDMM population, ROC analysis identified an optimal diagnostic MRI-based ADCmeanBM cut-off value of 410 µm2/s for diffuse BMI detection with a high specificity of 0.91 and a low sensitivity of 0.46 (area under curve: 0.71, Figure S4).
Discussion
We report here the first results concerning the added value of hybrid simultaneous WB-2-[18F]FDG-PET/MRI imaging in a prospective cohort of confirmed (according to IMWG) NDMM patients. This new hybrid technique represents the most powerful and complementary imaging tool available in MM: within 1 h, imaging can provide clinicians with both serial diagnostic and prognostic data. Achieving a simultaneous WB-2-[18F]FDG-PET/MRI imaging protocol has a significant practical benefit for patients as they only have to attend the hospital/clinic once for a full imaging overview, only receive a low radiation dose, and only have to be imaged once.
Focal bone lesion detection
In NDMM, detection of bone disease is one of the main goals of imaging. The presence of more than one FL ≥ 5 mm by MRI imaging is a biomarker of malignancy, i.e., an MDE, triggering the start of therapy [1].
In this study, global WB-2-[18F]FDG-PET/MRI imaging detected at least one FL in 75% of patients with symptomatic MM which is consistent with classic epidemiology of this disease [16]. An association was established between MRI and PET for FL detection (75% vs. 69%, respectively, p = 0.03) in symptomatic MM patients, which is inconsistent with results previously published by Westerland et al. [17] in a NDMM cohort composed almost exclusively of symptomatic patients. In this study, PET and WB-MRI (including DWI images) were obtained separately and WB-MRI detected significantly more patients with FL. It is possible that PET is more sensitive when performed simultaneously and precisely fused with MRI, thus facilitating an improved interpretation of abnormalities identified by PET. This assumption is supported by a recent preliminary study assessing WB-2-[18F]FDG-PET/MRI imaging in a retrospective heterogeneous population of patients with suspected or confirmed MM [18] (equal sensitivity of PET and MRI for FL detection).
In this study, global WB-2-[18F]FDG-PET/MRI imaging detected FL in 8/36 (22%) patients with SMM, resulting in a significant impact on clinical management in this population because all of these SMM patients subsequently received treatment: all had at least 2 FL ≥ 5 mm and 1 patient a single large FL with borderline serum free light chain ratio. No statistically significant association was reported between MRI and PET modalities for FL detection (p = 0.176), and MRI detected more SMM patients with FL than PET (22% vs. 11%).
The decrease in lesion size, the increase in ADC’s, or the disappearance of these supplemental MRI focal lesions were confirmed using the follow-up scans within the framework of therapy assessment to rule out the possibility of false-positive lesions. This is a novel finding and confirms the high diagnostic value of MRI including DWI for FL detection (especially small lesions) in early stages of this disease.
It is important to consider the complementarity of the MRI and PET data in order to obtain full benefit of hybrid WB-2-[18F]FDG-PET/MRI imaging. In addition to the diagnostic value of MRI and PET, the well documented important prognostic value of PET results should be also be mentioned. Indeed, recent large prospective and retrospective studies which assessed 2-[18F]FDG-PET/CT in NDMM showed several important results. Approximately 10% of patients with NDMM are 2-[18F]FDG-PET false-negative, this phenomenon being associated with low expression of hexokinase-2 [19], but these patients have a better prognosis than those with positive 2-[18F]FDG-PET [9]. Moreover, several PET-based biomarkers (number of FL > 3, high SUVmaxFL and/or high SUVmaxBMI, presence of PMD or EMD) were repeatedly correlated with worse outcome [6,7,8, 10, 20,21,22] so are useful to report.
Follow-up of patients included in this cohort should allow to demonstrate that 2-[18F]FDG-PET results also have a prognostic value when PET is acquired simultaneously and fused with MRI instead of CT.
Diffuse bone marrow involvement
Global WB-2-[18F]FDG-PET/MRI imaging detected diffuse BMI in 62% of symptomatic MM patients which is less than previously reported (90%, [19]). When analyzed alone, PET and MRI were equally effective (62% for both of them). In SMM patients, WB-2-[18F]FDGPET/MRI imaging detected diffuse BMI in 36% of cases. No association was established between MRI and PET for diffuse BMI detection (p = 0.136), and PET detected more diffuse BMI than MRI (36% vs. 22%) which is not in agreement with previously reported results [23]. This could be explained in part by the absence of clear standardization of MRI interpretation for diffuse BMI detection.
In this current study, we defined diffuse BMI by MRI imaging as a diffuse decreased signal on T1-in phase-DIXON weighted and diffuse increased signal throughout the marrow (relative to normal adjacent muscle) on high b-value DWI like in all other MRI studies and more generally as recommended by international guidelines [12]. However, patients with single diffuse mild increased signal throughout the marrow on high b-value DWI without decrease signal on T1-in phase-DIXON weighted images were not considered with diffuse BMI but more as unclear.
In our opinion, the prognostic value and the plasma cells’ biological characterization of diffuse BMI at baseline in NDMM are more important than their diagnostic value. Indeed, patients with MM have, by definition, a significant bone marrow infiltration of clonal plasma cells, and diffuse bone marrow involvement is not a MDE [1]. Furthermore, we have recently shown that the intensity of the bone marrow’s 2-[18F]FDG uptake was linearly correlated with survival of NDMM patients [10]; the higher the SUVmaxBM is, the shorter progression-free survival is. Others have shown that diffuse BMI identified by MRI imaging also seemed to be correlated with poor prognosis [24] even though they did not correlate this with 2-[18F]FDG-PET. Furthermore, Paschali et al. identified a correlation between the intensity of the bone marrow’s 2-[18F]FDG uptake and clonal plasma cell morphology. SUVmaxBM was significantly lower for the group of good differentiation vs. intermediate/low differentiation of clonal plasma cells [25].
In our cohort, SUVmaxBM and ADCmeanBM were weakly positively correlated, indicating that each feature brings different and complementary information. Finally, ROC curve analysis identified an optimal diagnostic MRI-based ADCmeanBM cut-off value of 410 µm2/s for diffuse BMI detection which matches perfectly with a previous study [18].
Conclusion
WB-2-[18F]FDG-PET/MRI could represent the next-generation imaging for MM. WB-2-[18F]FDG-PET/MRI imaging detected at least one FL in 75% of patients with symptomatic MM, and PET and MRI were equally effective at identifying patients with FL. WB-2-[18F]FDG-PET/MRI imaging detected FL in 22% of patients with SMM (with a higher diagnostic performance for MRI), resulting in a significant impact on clinical management in this population. SUVmax and ADCmean quantitative features were weakly or not correlated. PET could provide important prognostic data in addition to good diagnostic performance.
Abbreviations
- 2-[18F]FDG:
-
2-18F-fluorodeoxyglucose
- ADC:
-
Apparent diffusion coefficient
- BMI:
-
Bone marrow involvement
- CT:
-
Computed tomography
- DCE:
-
Dynamic contrast enhanced
- DWI:
-
Diffusion-weighted imaging
- EMD:
-
Extra-medullary disease
- FL:
-
Focal bone lesion
- IMWG:
-
International Myeloma Working Group
- MDE:
-
Myeloma defining event
- MM:
-
Multiple myeloma
- MRAC:
-
Magnetic resonance attenuation correction
- NDMM:
-
Newly diagnosed multiple myeloma
- PET:
-
Positron emission tomography
- PMD:
-
Para-medullary disease
- ROC:
-
Receiver-operating characteristic
- ROI:
-
Region of interest
- SMM:
-
Smoldering multiple myeloma
- SUVmax :
-
Maximal standardized uptake value
- WB-2-[18F]FDG-PET/MRI:
-
Whole-body 2-18F-fluorodeoxyglucose-positron emission tomography coupled with magnetic resonance imaging
References
Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–e548
Hillengass J, Usmani S, Rajkumar SV et al (2019) International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20(6):e302–e312
Hillengass J, Fechtner K, Weber M-A et al (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28(9):1606–10
Kastritis E, Moulopoulos LA, Terpos E, Koutoulidis V, Dimopoulos MA (2014) The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia 28(12):2402–2403
Zamagni E, Nanni C, Gay F et al (2016) 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 30(2):417–422
Moreau P, Attal M, Caillot D et al (2017) Prospective evaluation of magnetic resonance imaging and [18F] fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol 35(25):2911–2918
Zamagni E, Patriarca F, Nanni C et al (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118(23):5989–5995
Bartel TB, Haessler J, Brown TLY et al (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114(10):2068–2076
Abe Y, Ikeda S, Kitadate A et al (2019) Low hexokinase-2 expression-associated false-negative (18) F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging 46(6):1345–1350
Jamet B, Morvan L, Nanni C et al (2021) Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging 48(4):1005–1015
Benaniba L, Tessoulin B, Trudel S et al (2019) The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. BMC Cancer 19(1):855
Messiou C, Hillengass J, Delorme S et al (2019) Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS). Radiology 291(1):5–13
Dutoit J, Vanderkerken M, Verstraete KL (2013) Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma. Eur J Radiol 82(9):1444–1452
Nanni C, Zamagni E, Versari A et al (2016) Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 43(3):414–421
Messiou C, Collins DJ, Morgan VA, Desouza NM (2011) Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol 21(8):1713–1718
Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21–33
Westerland O, Amlani A, Kelly-Morland C et al (2021) Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma. Eur J Nucl Med Mol Imaging 48(8):2558–2565
Burns R, Mulé S, Blanc-Durand P et al (2021) Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma. Eur Radiol. 32(5):3085–3096
Rasche L, Angtuaco E, McDonald JE et al (2017) Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130(1):304
Aljama MA, Sidiqi MH, Buadi FK et al (2018) Utility and prognostic value of 18F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. Am J Hematol 93(12):1518–1523
Jung S-H, Kwon SY, Min J-J et al (2019) 18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the revised international staging system. Eur J Nucl Med Mol Imaging 46(1):107–115
Michaud-Robert AV, Zamagni E, Carlier T et al (2020) Glucose metabolism quantified by SUVmax on baseline FDG-PET/CT predicts survival in newly diagnosed multiple myeloma patients: combined harmonized analysis of two prospective phase III trials. Cancers (Basel) 12(9):2532
Cavo M, Terpos E, Nanni C et al (2017) International Myeloma Working Group. Review Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 18:e206-2017
Moulopoulos LA, Dimopoulos MA, Christoulas D et al (2010) Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia 24:1206–1212
Paschali A, Panagiotidis E, Triantafyllou T et al (2021) A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy. Eur J Nucl Med Mol Imaging 48(5):1487–1497
Funding
This work has been supported in part by grants from the French National Agency for Research called “Investissements d’Avenir” IRON Labex n°ANR-11-LABX-0018–01 and INCa-DGOS-Inserm_12558 (SIRIC ILIAD).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Francoise Kraeber-Bodere (FKB), head of Nantes University Hospital’s department of nuclear medicine.
Conflict of interest
The authors declare no competing interests.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Informed consent
Written informed consent was obtained from all subjects (patients) in this study.
Ethical approval
Institutional review board approval was obtained.
Cohort overlap
Some study subjects or cohorts have previously been reported in Benaniba L, Tessoulin B, Trudel S, et al The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. BMC Cancer. 2019;19(1):855.
Methodology
• prospective
• diagnostic study
• performed at one institution
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Jamet, B., Carlier, T., Bailly, C. et al. Hybrid simultaneous whole-body 2-[18F]FDG-PET/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results. Eur Radiol 33, 6438–6447 (2023). https://doi.org/10.1007/s00330-023-09593-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-023-09593-1